

Resource Summary Report

Generated by [dkNET](#) on Aug 7, 2026

Recombinant Anti-CCR7 antibody [EPR23192-57]

RRID:AB_2922673

Type: Antibody

Proper Citation

Abcam Cat# ab253187, RRID:AB_2922673

Antibody Information

URL: http://antibodyregistry.org/AB_2922673

Proper Citation: Abcam Cat# ab253187, RRID:AB_2922673

Target Antigen: CCR7

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: IHC-Fr, IHC-P

Antibody Name: Recombinant Anti-CCR7 antibody [EPR23192-57]

Description: This recombinant monoclonal targets CCR7

Target Organism: rat, mouse, human

Clone ID: EPR23192-57

Antibody ID: AB_2922673

Vendor: Abcam

Catalog Number: ab253187

Record Creation Time: 20250819T221015+0000

Record Last Update: 20250820T012009+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-CCR7 antibody [EPR23192-57].

No alerts have been found for Recombinant Anti-CCR7 antibody [EPR23192-57].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Lu M, et al. (2026) Homeostatic maturation programs drive human cDC2s into a tolerogenic state. *Immunity*, 59(5), 1201.

Karakousi T, et al. (2026) IFN γ -dependent metabolic reprogramming restrains an immature, pro-metastatic lymphatic state in melanoma. *Cancer cell*, 44(4), 792.

Dong Z, et al. (2026) Engineering oral commensal nanovaccines to activate mucosal-systemic immune cascades against tumor. *Cell host & microbe*.

Zhang Y, et al. (2024) CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis. *Cancer cell*, 42(8), 1370.

Yasumizu Y, et al. (2024) Spatial transcriptomics elucidates medulla niche supporting germinal center response in myasthenia gravis-associated thymoma. *Cell reports*, 43(9), 114677.

Wu SY, et al. (2023) CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer. *Med (New York, N.Y.)*, 4(6), 373.

Wen J, et al. (2022) Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma. *EBioMedicine*, 86, 104371.